Anxiety mediates the association between cannabis use and attenuated positive psychotic symptoms

Psychiatry Research

Volumn 218, Issue 1-2, 2014, Pages 180-186

  Reeves, Lauren E ^a   Anglin, Deidre M ^b   Heimberg, Richard G ^a   Gibson, Lauren E ^a   Fineberg, Anna M ^a   Maxwell, Seth D ^a   Kerns, Connor M ^a   Ellman, Lauren M ^a  

^a TEMPLE UNIVERSITY   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Anxiety; Attenuated psychotic symptoms; Clinical high risk; Prodromal; Psychosis

Indexed keywords

ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; ATTENUATED POSITIVE PSYCHOTIC SYMPTOM; CANNABIS USE; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; DEPRESSION; DISEASE ASSOCIATION; DISTRESSING ATTENUATED POSITIVE PSYCHOTIC SYMPTOM; DRUG USE FREQUENCY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRODROMAL QUESTIONNAIRE; PRODROMAL SYMPTOM; PSYCHOSIS; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SOCIAL PHOBIA; SOCIAL PHOBIA SCALE; STATE TRAIT ANXIETY INVENTORY; ANXIETY; CANNABIS ADDICTION; COMPLICATION; PERSONALITY TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANXIETY; DEPRESSION; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; PERSONALITY INVENTORY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUESTIONNAIRES; YOUNG ADULT;

EID: 84902080143     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.03.040     Document Type: Article

References (70)

1. American Psychological Association Diagnostic and Statistical Manual of Mental Disorders 2000, APA, Washington, D.C., (text revision). fourth edition.
2. Andreasson S., Allebeck P., Engstrom A., Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987, 2:1483-1486.
3. Andresen E.M., Malmgren J.A., Carter W.B., Patrick D.L. Screening for depression in well older adults: evaluation of a short form of the CES-D. American Journal of Preventive Medicine 1994, 10:77-84.
4. Anglin D.M., Corcoran C.M., Brown A.S., Chen H., Lighty Q., Brook J.S., Cohen P.R. Early cannabis use and schizotypal personality disorder symptoms from adolescence to middle adulthood. Schizophrenia Research 2012, 137:42-49.
5. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British Medical Journal 2002, 325:1212-1213.
6. Auther A.M., McLaughlin D., Carrion R.E., Nagachandran P., Correll C.U., Cornblatt B.A. Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome. Psychological Medicine 2012, 42:2485-2497.
7. Bell D. The experimental reproduction of amphetamine psychosis. Archives of General Psychiatry 1973, 29:35-40.
8. Bieling P.J., Antony M.M., Swinson R.P. The state-trait anxiety inventory, trait version: structure and content re-examined. Behaviour Research and Therapy 1998, 36:777-788.
9. Binbay T., Drukker M., Elbi H., Aksu Tanik F., Ozkinay F., Onay H., Zagli N., van Os J., Alpetkin K. Testing the psychosis continuum: differential impact of genetic and nongenetic risk factors and comorbid psychopathology across the entire spectrum of psychosis. Schizophrenia Bulletin 2012, 38:992-1002.
10. Bolton J.M., Robinson J., Sareen J. Self-medication of mood disorders with alcohol and drugs in the national epidemiologic survey on alcohol and related conditions. Journal of Affective Disorders 2009, 115:367-375.
11. Buckner J.D., Heimberg R.G., Schneier F.R., Liu S., Wang S., Blanco C. The relationship between cannabis use disorders and social anxiety disorder in the national epidemiological study of alcohol and related conditions (NESARC). Drug and Alcohol Dependence 2012, 124:128-134.
12. Caspari D. Cannabis and schizophrenia: results of a follow-up study. European Archives of Psychiatry and Clinical Neuroscience 1999, 249:45-49.
13. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biological Psychiatry 2005, 57:1117-1127.
14. Corcoran C.M., Kimhy D., Stanford A., Khan S., Walsh J., Thompson J., Schobel S., Harkavy-Friedman J., Goetz R., Colibazzi T., Cressman V., Malaspina D. Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophrenia Research 2008, 106:286-293.
15. Fergusson D.M., Horwood L.J., Swain-Campbell N.R. Cannabis dependence and psychotic symptoms in young people. Psychological Medicine 2003, 33:15-21.
16. Furmark T., Tillfors M., Marteinsdottir I., Fischer H., Pissiota A., Langstrom B., Fredrikson M. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Archives of General Psychiatry 2002, 59:425-433.
17. Hall W., Degenhardt L. Cannabis use and psychosis: a review of clinical and epidemiological evidence. Australian and New Zealand Journal of Psychiatry 2000, 34:26-34.
18. Hayes, A.F., 2012. PROCESS: A Versatile Computational Tool for Observed Variable Mediation, Moderation, and Conditional Process Modeling. Retrieved from. http://www.afhayes.com/public/process2012.pdf.
19. Heimberg R.G., Mueller G.P., Holt C.S., Hope D.A. Assessment of anxiety in social interaction and being observed by others: the social interaction anxiety scale and the social phobia scale. Behavior Therapy 1992, 23:53-73.
20. Johns A. Psychiatric effects of cannabis. British Journal of Psychiatry 2001, 178:116-122.
21. Johns L.C., Cannon M., Singleton N., Murray R.M., Farrell M., Brugha T., Bebbington P., Jenkins R., Meltzer H. Prevalence and correlates of self-reported psychotic symptoms in the British population. British Journal of Psychiatry 2004, 185:298-305.
22. Kaymaz N., Drukker M., Lieb R., Wittchen H.-U., Werbeloff N., Weiser M., Lataster T., van Os J. Do subthreshold psychotic experiences predict clinical outcomes in unselected non-help-seeking population-based samples? A systematic review and meta-analysis, enriched with new results. Psychological Medicine 2012, 42:2239-2253.
23. Kelleher I., Cannon M. Psychotic-like experiences in the general population: characterizing a high-risk group for psychosis. Psychological Medicine 2011, 41:1-6.
24. Khan S.S., Secades-Villa R., Okuda M., Wang S., Perez-Fuentes G., Kerridge B.T., Blanco C. Gender differences in cannabis use disorders: results from the national epidemiologic survey of alcohol and related conditions. Drug and Alcohol Dependence 2013, 130:101-108.
25. Kline E., Wilson C., Ereshefsky S., Denenny D., Thompson E., Pitts S.C., Bussell K., Reeves G., Schiffman J. Psychosis risk screening in youth: a validation study of three self-report measures of attenuated psychosis symptoms. Schizophrenia Research 2012, 141:72-77.
26. Kohout F.J., Berkman L.F., Evans D.A., Cornoni-Huntley J. Two shorter forms of the CES-D depression symptoms index. Journal of Aging and Health 1993, 5:179-193.
27. Kuepper R., van Os J., Lieb R., Wittchen H.-U., Hofler M., Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. British Medical Journal 2011, 342:d738.
28. Lang U.E., Hellweg R., Kalus P., Bajbouj M., Lenzen K.P., Sander T., Kunz D., Gallinat J. Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology (Berlin, Germany) 2005, 180:95-99.
29. Linszen D.H., Dingemans P.M., Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 1994, 51:273-279.
30. Loewy R.L., Bearden C.E., Johnson J.K., Raine A., Cannon T.D. The prodromal questionnaire (PQ): preliminary validation of a self-report screening measure for prodromal and psychotic syndromes. Schizophrenia Research 2005, 79:117-125.
31. Loewy R.L., Johnson J.K., Cannon T.D. Self-report of attenuated psychotic experiences in a college population. Schizophrenia Research 2007, 93:144-151.
32. Loewy R.L., Therman S., Manninen M., Huttunen M.O., Cannon T.D. Prodromal psychosis screening in adolescent psychiatry clinics. Early Intervention in Psychiatry 2012, 6:69-75.
33. Macleod J., Oakes R., Copello A., Crome I., Egger M., Hickman M., Oppenkowski T., Stokes-Lampard H., Davey Smith G. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 2004, 363:1579-1588.
34. Matheson S.L., Shepherd A.M., Laurens K.R., Carr V.J. A systematic meta-review grading the evidence for non-genetic risk factors and putative antecedents of schizophrenia. Schizophrenia Research 2011, 133:133-142.
35. Mattick R.P., Clarke J.C. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behaviour Research and Therapy 1998, 36:455-470.
36. Miller T.J., McGlashan T.H., Rosen J.L., Somjee L., Markovich P.J., Stein K., Woods S.W. Prospective diagnosis of the initial prodrome for schizophrenia based on the structured interview for prodromal syndromes: preliminary evidence of interrater reliability and predictive validity. American Journal of Psychiatry 2002, 159:863-865.
37. Moore T.H.M., Zammit S., Lingford-Hughes A., Barnes T.R.E., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
38. Myles-Worsley M., Weaver S., Blailes F. Comorbid depressive symptoms in the developmental course of adolescent-onset psychosis. Early Interventions in Psychiatry 2007, 15:183-190.
39. Najolia G.M., Buckner J.D., Cohen A.S. Cannabis use and schizotypy: the role of social anxiety and other negative affective states. Psychiatry Research 2012, 200:660-668.
40. O'Farrell T.J., Fals-Stewart W., Murphy M. Concurrent validity of a brief self-report drug use frequency measure. Addictive Behaviors 2003, 28:327-337.
41. Osuch E., Vingilis E., Ross E., Forster C., Summerhurst C. Cannabis use, addiction risk and functional impairment in youth seeking treatment for primary mood or anxiety concerns. International Journal of Adolescent Medicine and Health 2013, 25:309-314.
42. Patton G.C., Coffey C., Carlin J.B., Degenhardt L., Lynskey M., Hall W. Cannabis use and mental health in young people: cohort study. British Medical Journal 2002, 325:1195-1198.
43. Phillips L.J., Curry C., Yung A.R., Yuen H.P., Adlard S., McGorry P.D. Cannabis use is not associated with the development of psychosis in an 'ultra' high-risk group. Australian and New Zealand Journal of Psychiatry 2002, 36:800-806.
44. Preacher K.J., Hayes A.F. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behavior Research Methods 2008, 40:879-891.
45. Radloff L.S. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement 1977, 1:385-401.
46. Roberts R.E. Reliability of the CES-D scale in different ethnic contexts. Psychiatry Research 1980, 2:125-134.
47. Roberts R.E., Vernon S.W., Rhoades H.M. Effects of language and ethnic status on reliability and validity of the center for epidemiologic studies-depression scale with psychiatric patients. Journal of Nervous and Mental Disease 1989, 177:581-592.
48. Robinson J., Sareen J., Cox B.J., Bolton J. Self-medication of anxiety disorders with alcohol and drugs: results from a nationally representative sample. Journal of Anxiety Disorders 2009, 23:38-45.
49. Rosen J.L., Miller T.J., D[U+05F3]Andrea J.T., McGlashan T.H., Woods S.W. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophrenia Research 2006, 85:124-131.
50. Ruiz-Veguilla M., Barrigon M.L., Hernandez L., Rubio J.L., Gurpegui M., Sarramea F., Cervilla J., Gutierrez B., James A., Ferrin M. Dose-response effect between cannabis use and psychosis liability in a non-clinical population: evidence from a snowball sample. Journal of Psychiatric Research 2013, 47:1036-1043.
51. Rule W.R., Traver M.D. Test-retest reliabilities of state-trait anxiety inventory in a stressful social analogue situation. Journal of Personality Assessment 1983, 47:276-277.
52. Smeets G., Merckelbach H., Griez E. Panic disorder and right-hemisphere reliance. Anxiety, Stress & Coping: An International Journal 1997, 10:245-255.
53. Smith M.J., Thirthalli J., Abdallah A.B., Murray R.M., Cottler L.B. Prevalence of psychotic symptoms in substance users: a comparison across substances. Comprehensive Psychiatry 2009, 50:245-250.
54. Sobell L.C., Sobell M.B. Timeline Followback user[U+05F3]s guide: A Calendar Method for Assessing Alcohol and Drug Use 1996, Addiction Research Foundation, Toronto, Ontario, Canada.
55. Spielberger C.D., Gorsuch R.L., Lushene R., Vagg P.R., Jacobs G.A. Manual for the State-Trait Anxiety Inventory 1983, Consulting Psychologists Press, Palo Alto, CA.
56. Substance Abuse and Mental Health Services Administration, 2013. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Substance Abuse and Mental Health Services Administration, Rockville, MD.
57. Thorup A., Peterson L., Jeppesen P., Ohlenschlaeger J., Christensen T., Krarup G., Jorgensen P., Nordentoft M. Gender differences in young adults with first-episode schizophrenia spectrum disorders at baseline in the Danish OPUS study. Journal of Nervous and Mental Disease 2007, 195:396-405.
58. Van Dam N.T., Earleywine M., DiGiacomo G. Polydrug use, cannabis, and psychosis-like symptoms. Human Psychopharmacology: Clinical and Experimental 2008, 23:475-485.
59. Van Dam N.T., Bedi G., Earleywine M. Characteristics of clinically anxious versus non-anxious regular, heavy marijuana users. Addictive Behaviors 2012, 37:1217-1223.
60. van Gastel W.A., Wigman J.T., Monshouwer K., Kahn R.S., van Os J., Boks M.P., Vollebergh W.A. Cannabis use and subclinical positive psychotic experiences in early adolescence: findings from a Dutch survey. Addiction 2012, 107:381-387.
61. van Laar M., van Dorsselaer S., Monshouwer K., de Graaf R. Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population?. Addiction 2007, 102:1251-1260.
62. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. American Journal of Epidemiology 2002, 156:319-327.
63. van Os J., Linscott R.J., Myin-Germeys I., Delespaul P., Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychological Medicine 2009, 39:179-195.
64. van Os J., Linscott R.J. The extended psychosis phenotype-relationship with schizophrenia and with ultrahigh risk status for psychosis. Schizophrenia Bulletin 2012, 38:227-230.
65. White H.R., Labouvie E.W., Papadaratsakis V. Changes in substance use during the transition to adulthood: a comparison of college students and their noncollege age peers. Journal of Drug Issues 2005, 35:281-306.
66. Wigman J.T.W., van Nierop M., Vollebergh W.A.M., Lieb R., Beesdo-Baum K., Wittchen H.-U., van Os J. Evidence that psychotic symptoms are prevalent in disorders of anxiety and depression, impacting on illness onset, risk, and severity - implications for diagnosis and ultra-high risk research. Schizophrenia Bulletin 2012, 38:247-257.
67. Wittchen H.-U., Frohlich C., Behrendt S., Gunther A., Rehm J., Zimmerman P., Lieb R., Perkonigg A. Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. Drug and Alcohol Dependence 2007, 88:60-70.
68. Wolitzky-Taylor K., Bobova L., Zinbarg R.E., Mineka S., Craske M.G. Longitudinal investigation of the impact of anxiety and mood disorders in adolescence on subsequent substance use disorder onset and vice versa. Addictive Behaviors 2012, 37:982-985.
69. Yung A.R., Phillips L.J., Yuen H.P., McGorry P.D. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophrenia Research 2004, 67:131-142.
70. Zammit S., Allebeck P., Andreasson S., Lundberg I., Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. British Medical Journal 2002, 325:1199-1201.